[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"elective-cardiac-surgery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:elective-cardiac-surgery":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,60],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":39,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":59},"100537589","phase-2-intravenous-fish-oil-based-lipid-emulsion-to-enhance-recovery-in-high-risk-cardiac-surgery-patients-100537589",false,"NCT06279793","Intravenous Fish Oil Based Lipid Emulsion to Enhance Recovery in High-Risk Cardiac Surgery Patients","Intravenous Fish Oil Based Lipid Emulsion to Enhance Recovery in High-Risk Cardiac Surgery Patients: a Phase II Multicenter Trial - A Randomized, Placebo-controlled Trial -","MODIFY CSX","Inclusion Criteria:\n\n1. Written informed consent prior to study participation\n2. Adult patients (≥ 18 years)\n3. Patients scheduled to undergo elective cardiac surgery with the use of CPB, who are defined as high risk based on having (i) one of the following surgical procedures: valvular heart surgery only, CABG, combined valve and CABG, multiple valve surgeries, combined cardiac procedures, aortic surgical procedures (aortic arch and\u002For descending aorta; aortic valve+ascending aorta) and (ii) at least one of the following additional risk factors: (a) a high perioperative risk profile, defined as predicted operative mortality of ≥8% (EuroSCORE II), (b) age ≥70, (c) Clinical Frailty Score 4 or more, (d) urgent surgery (defined as to be performed within 24-48 hours after admission), (e) left ventricular ejection fraction \\\u003C35%\n\nExclusion Criteria:\n\n1. Known hypersensitivity to fish oil\u002Ffish products or egg protein\n2. Pregnancy or lactation period\n3. Previous history of chronic atrial fibrillation, atrial flutter and\u002For atrial tachyarrhythmia\n4. Inability or unwillingness of individual to give written informed consent\n5. Not expected to survive an additional 48 hours from screening evaluation\n6. Lack of commitment to full, aggressive care (anticipated withholding or withdrawing treatments in the first week but isolated \"Do not Resuscitate\" \\[DNR\\] acceptable)\n7. Patients admitted with diabetic ketoacidosis or non-ketotic hyperosmolar coma\n8. Patients receiving extracorporeal mechanical assist device (e.g. ECLS, or IABP) or advanced heart failure therapies (e.g. TAH, VAD)\n9. Enrolment in anyinterventional trial within the last 30 days\n10. Already receiving FO-containing medical nutrition products\n11. Severe malnutrition (as defined by the BMI \\\u003C18.5)\n12. Severe liver dysfunction defined by Child Pugh Class C.\n13. Severe chronic kidney dysfunction defined by the National Kidney Foundation (NKF) stage 4 and 5 by using the glomerular filtration rate (GFR \\\u003C30ml\u002Fmin)\n14. Known severe coagulation disorder","ALL","18 Years",{"count":20,"type":21},550,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The MODIFY CSX study is a prospective, randomized, placebo-controlled trial conducted in heart centers in Germany and Italy.\n\nA total of 550 high-risk cardiac surgery patients will receive either 0.20 g fish oil\u002Fkg body weight (BW) + standard of care versus same volume of placebo (NaCl) + standard of care.",[27,28,29,30,31,32,33,34,35,36,37,38],"Intensive Care Unit","Coronary Artery Bypass Grafting (CABG)","High Risk Patients","Cardiopulmonary Bypass","Elective Cardiac Surgery","Valvular Heart Surgery","Multiple Valve Surgeries","Combined Cardiac Procedures","Aortic Surgical Procedures","Adult Patients ≥ 18 Years","Combined Valve and CABG","Combined Cardiac and Aortic Surgical Procedures",[40,41,42,43,44,45,46],"intensive care unit","elective cardiac surgery","fish oil","medical nutrition therapy","atrial fibrillation","atrial flutter","atrial tachycardia","RECRUITING","2026-02-19",{"date":50,"type":51},"2026-02-23","ACTUAL",{"date":53,"type":51},"2024-02-15",{"date":55,"type":21},"2030-09",{"name":57,"class":58},"GCP-Service International West GmbH","INDUSTRY",10,{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":4,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":67,"targetDuration":4,"studyType":22,"phases":69,"briefSummary":71,"conditions":72,"keywords":73,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":87},"100555772","parasternal-blockade-and-serum-lactate-in-cardiac-surgery-100555772","NCT06516432","Parasternal Blockade and Serum Lactate in Cardiac Surgery","Serum Lactate in the Application of Parasternal Blockade in Trans and Post Anesthetic Stages in Cardiac Surgery","Inclusion Criteria:\n\n* Adult patients older than 18 years\n* Either sex\n* ASA II-III\n* Patients who underwent cardiac surgery with median sternotomy and use of cardiopulmonary bypass.\n\nExclusion Criteria:\n\n* Patients with pre-existing conditions that could independently affect serum lactate levels.",{"count":68,"type":21},86,[70],"NA","Serum lactate level is a key indicator of tissue perfusion. Parasternal blockade is associated with reduced postoperative inflammatory response by inhibiting stress response, leading to better outcomes. Elevated lactate levels help identify patients at risk of postoperative morbidity and mortality. This analytical cross-sectional study evaluated the association between parasternal blockade and serum lactate levels in patients undergoing elective cardiac surgery in 2022 at Specialty Hospital CMNO. Patients with and without parasternal block were compared for changes in serum lactate levels during and after anesthesia within the first 24 hours.",[31],[74,75,76],"Parasternal block","Cardiac surgery","Serum lactate","2024-07-18",{"date":79,"type":51},"2024-07-24",{"date":81,"type":51},"2024-01-01",{"date":83,"type":21},"2024-12-31",{"name":85,"class":86},"Instituto Mexicano del Seguro Social","OTHER_GOV",1]